New Antibiotics for Drug-Resistant Bacterial Infections
Novel Biamyxins targeting multidrug resistant Gram-negative bacterial infections
This project is creating new antibiotics called biamyxins to fight serious infections caused by drug-resistant bacteria.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | State University of New York at Buffalo NIH-funded |
| Lab location | 1 site (Amherst, United States) |
| Project ID | NIH-11129737 on NIH RePORTER |
What this research studies
Many severe infections in hospitals are caused by Gram-negative bacteria that are becoming resistant to current medicines, making them very hard to treat. This is a major health concern worldwide, as existing antibiotics are often ineffective against these tough pathogens. Our team is developing a new type of antibiotic, called biamyxins, which are designed to specifically target and bind to the outer layer of these resistant bacteria. These new medicines aim to overcome the resistance that makes other treatments ineffective, offering a fresh approach to combat these dangerous infections.
Who could benefit from this research
Good fit: Patients with severe, multidrug-resistant Gram-negative bacterial infections, particularly those caused by Acinetobacter baumannii, Enterobacteriaceae, or Pseudomonas aeruginosa, could potentially benefit from this research.
Not a fit: Patients with infections caused by bacteria that are not Gram-negative or are not multidrug-resistant would likely not receive direct benefit from this specific antibiotic approach.
Why it matters
Potential benefit: If successful, these new biamyxin antibiotics could offer a much-needed treatment option for patients suffering from life-threatening, multidrug-resistant bacterial infections.
How similar studies have performed: This project describes a new class of antibiotics, biamyxins, suggesting a novel approach to combat drug-resistant Gram-negative bacteria.
Where this research is happening
Amherst, United States
- State University of New York at Buffalo — Amherst, United States (Active)
Researchers
- Principal investigator: Zhao, Yanan — State University of New York at Buffalo
- Study coordinator: Zhao, Yanan
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.